id: NEW:aud_pharmacotherapy_availability_to_alcohol_use_disorder
name: AUD Pharmacotherapy Availability â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:aud_pharmacotherapy_availability
  node_name: AUD Pharmacotherapy Availability
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Laboratory trials screen medications for efficacy using cue-exposure paradigms'
- 'Step 2: Medication-related reductions in cue-reactivity serve as early efficacy signals'
- 'Step 3: Successful laboratory screening informs medications development pipeline'
- 'Step 4: Effective medications become available for clinical AUD treatment'
- 'Step 5: Access to effective pharmacotherapy reduces AUD severity and relapse risk'
evidence:
  quality_rating: A
  n_studies: 36
  primary_citation: 'Lindsay R Meredith et al. 2023. "Testing pharmacotherapies for alcohol use disorder
    with cue exposure paradigms: A systematic review and quantitative synthesis of human laboratory trial
    methodology.." https://doi.org/10.1111/acer.15143'
  supporting_citations:
  - 19 different medications tested across 36 trials in systematic review
  - 8 pharmacotherapies demonstrated efficacy on cue-induced craving outcomes
  - Additional citations require full-text access for specific medication trial identification
  doi: 10.1111/acer.15143
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: 'The review identified that 8 pharmacotherapies demonstrated small-to-medium effects (Cohen''s
  d range: |0.24 - 0.64|) on reducing cue-induced craving compared to placebo across 28 randomized trials.
  These laboratory findings inform the medications development pipeline for AUD treatment, with the upper
  effect size of 0.64 representing the strongest medication effects observed.'
quantitative_effects:
  effect_size:
    value: 0.64
    type: standardized_mean_difference
  sample_size: 1640
moderators:
- name: paradigm_design_heterogeneity
  direction: weakens
  strength: moderate
  description: Heterogeneous cue exposure design, parameter testing, and outcome reporting across trials
    may limit comparability and medication development efficiency
- name: outcome_reporting_quality
  direction: weakens
  strength: moderate
  description: Relatively few trials included means for craving by medication condition in text (k=7)
    or figure (k=18), limiting meta-analytic precision
structural_competency:
  equity_implications: The pathway from medication development to AUD treatment involves multiple structural
    factors including research funding allocation, pharmaceutical development incentives, FDA approval
    processes, insurance coverage decisions, and healthcare system capacity for addiction treatment. Inequities
    in access to AUD pharmacotherapy reflect broader disparities in substance use treatment access, with
    underserved populations facing greater barriers to medication-assisted treatment. The review's focus
    on standardizing methodology aims to accelerate medication development, which could ultimately improve
    treatment access.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.440534'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
